D

HTA ID Drug Brand Indication Assessment status Date
22073 Drospirenone/estetrol monohydrate Drovelis® Drospirenone/estetrol monohydrate is indicated for oral contraception. Rapid Review Complete 6th July 2023
- Dulaglutide Trulicity® As monotherapy for the treatment of adult patients with T2DM when diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications. Dulaglutide is indicated as an add-on therapy in combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control. Rapid review complete 29th April 2015
23047 Dupilumab Dupixent® Dupilumab (Dupixent®) is indicated for the treatment of adults and adolescents 12 years and older, weighing at least 40 kg, with eosinophilic oesophagitis (EoE) who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy. Rapid Review Complete 7th September 2023
19056 Dupilumab Dupixent® For the treatment of moderate-to-severe atopic dermatitis in adolescents 12 years and older who are candidates for systemic therapy. Rapid review complete 17th January 2020
23043 Dupilumab Dupixent® Dupilumab (Dupixent®) is indicated for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. Rapid Review Complete 24th August 2023
23044 Dupilumab Dupixent® Dupilumab (Dupixent®) is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with medium to high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment. Rapid Review Complete 5th September 2023
21063 Dupilumab Dupixent® For adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance. Rapid review complete 14th March 2024
21035 Dupilumab Dupixent® For severe atopic dermatitis in children 6 to 11 years old who are candidates for systemic therapy. Rapid review complete 23rd September 2021
23042 Dupilumab Dupixent® Dupilumab is indicated for the treatment of severe atopic dermatitis in children aged 6 months to 6 years old who are candidates for systemic therapy. Rapid Review Complete 1st September 2023
23046 Dupilumab Dupixent® Dupilumab (Dupixent®) is indicated as an add-on therapy with intranasal corticosteroids, for the treatment of adults with severe chronic rhinosinusitis with nasal polyposis for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control. Rapid Review Complete 5th September 2023
- Dupilumab Dupixent® For treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy. NCPE Assessment Process Complete 12th December 2019
- Durvalumab Imfinzi® For the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC)  in adults whose tumours express PD-L1 ≥1% on tumour cells and whose disease has not progressed following platinum-based chemo-radiation therapy (CRT). NCPE Assessment Process Complete 7th May 2020
21033 Durvalumab Imfinzi® In combination with etoposide and either carboplatin or cisplatin, for the first-line treatment of adult patients with extensive-stage small cell lung cancer. Rapid review complete 9th September 2021
23009 Durvalumab Imfinzi® Durvalumab in combination with gemcitabine and cisplatin is indicated for the first-line treatment of adults with unresectable or metastatic biliary tract cancer. Full HTA submission received from Applicant 4th October 2023